Fifteen Korean Drug Firms Granted Innovative Status Charged With Unfair Trade Practices
This article was originally published in PharmAsia News
Old habits seem to die hard as 15 Korean pharma companies among 43 granted tax breaks and financial incentives to compete at home and abroad are charged with unfair trade practices, including making rebate payments to secure orders.
You may also be interested in...
SEOUL - South Korea's local pharmas are clambering to tie the knot with multinationals and among themselves in what appears to be a "marriage of necessity" in a desperate attempt to survive a government crackdown on rebates, on which locals have long depended
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.